A study to investigate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of a CD19/CD20 T-cell engager in participants with B-cell driven ARD.

2025-522932-15-00 Protocol 300134 Human pharmacology (Phase I) - Other Authorised, recruitment pending

Status Authorised, recruitment pending · 5 EU/EEA countries · 13 sites · Protocol 300134

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Authorised, recruitment pending
Participants planned 45
Countries 5
Sites 13

Systemic Lupus Erythematosus

Key facts

Sponsor
Glaxosmithkline Research & Development Limited
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Decision date (initial)
2026-03-23
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Systemic Lupus Erythematosus

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Glaxosmithkline Research & Development Limited

Sponsor organisation
Glaxosmithkline Research & Development Limited
Address
79 New Oxford Street
City
London
Postcode
WC1A 1DG
Country
United Kingdom

Scientific contact point

Organisation
Glaxosmithkline Research & Development Limited
Contact name
EU GSK Clinical Trials Call Center

Public contact point

Organisation
Glaxosmithkline Research & Development Limited
Contact name
EU GSK Clinical Trials Call Center

Locations

5 EU/EEA countries · 13 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Authorised, recruitment pending 2 2
Germany Authorised, recruitment pending 6 3
Italy Authorised, recruitment pending 2 2
Poland Authorised, recruitment pending 4 3
Spain Authorised, recruitment pending 4 3
Rest of world
Argentina, Panama, Brazil, United States, Japan
27

Investigational sites

France

2 sites · Authorised, recruitment pending
Centre Hospitalier Universitaire De Bordeaux
Service de Médecine Interne et Immunologie Clinique, 1 Rue Jean Burguet, 33000, Bordeaux
Centre Hospitalier Universitaire De Toulouse
Medecine interne et immunologie Clinique, 1 Avenue Du Professeur Jean Poulhes, Tsa 50032, Toulouse Cedex 9

Germany

3 sites · Authorised, recruitment pending
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
I. Medizinische Klinik und Poliklinik, Langenbeckstrasse 1, Oberstadt, Mainz
Universitaetsklinikum Jena KöR
Klinik für Innere Medizin III, Am Klinikum 1, Lobeda, Jena
Universitaetsklinikum Koeln AöR
Innere Medizin I, Kerpener Strasse 62, Lindenthal, Cologne

Italy

2 sites · Authorised, recruitment pending
Humanitas Mirasole S.p.A.
Unità di Fase I, Via Alessandro Manzoni 56, 20089, Rozzano
University Hospital Of Ferrara
Unità Clinica di Fase 1 Oncologia-Reumatologia, Via Aldo Moro 8, 44124, Ferrara

Poland

3 sites · Authorised, recruitment pending
Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher
Klinika Wczesnego Zapalenia Stawow, Ul. Spartanska 1, 02-637, Warsaw
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie
Oddzial Kliniczny Reumatologii, Immunologii i Chorob Wewnetrznych, Ul. Macieja Jakubowskiego 2, 30-688, Cracow
Uniwersytecki Szpital Kliniczny W Poznaniu
Osrodek Wczesnych Faz, Ul. Dluga 1/2, 61-848, Poznan

Spain

3 sites · Authorised, recruitment pending
Hospital Universitario La Paz
Internal Medicine, Paseo De La Castellana 261, 28046, Madrid
Hospital De La Santa Creu I Sant Pau
Rheumatology, Carrer De San Quinti 89, 08041, Barcelona
Hospital Clinico San Carlos
Clinical Pharmacology, Calle Del Profesor Martin Lagos Sn, 28040, Madrid

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-11-14 Spain Acceptable
2026-03-23
2026-03-23